457 filings
Page 4 of 23
6-K
l85bm
11 Apr 23
Current report (foreign)
6:01am
6-K
wj54ptkbm
4 Apr 23
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
6:51am
6-K
gfd9b
31 Mar 23
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
6:06am
6-K
78qsngf3l08lcvk4kjc
14 Mar 23
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
9:46am
6-K
6c2 0iyla5
8 Mar 23
Current report (foreign)
6:04am
6-K
asohqz2cl zjn2r4hf9
6 Mar 23
Vesting of awards under the Long Term Incentive Plan
6:01am
6-K
y0o5gpzz86hyxbzxzh
28 Feb 23
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
6:09am
6-K
2a2zqyn0
27 Feb 23
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
6:29am
6-K
ew499h40jygvv
31 Jan 23
HUTCHMED to Announce 2022 Final Results
6:03am
6-K
6xibfhsvb
23 Jan 23
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
6:39am
6-K
uhqxarl721skf240k
18 Jan 23
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
9:13pm
6-K
7rgsmp ob6rmc
3 Jan 23
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
6:01am
6-K
lwv j8q58w1gn
30 Dec 22
Current report (foreign)
6:05am
6-K
0frlti
19 Dec 22
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
6:01am
6-K
y20 wufownajcy5yh
15 Nov 22
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
6:03am
6-K
iypz6
14 Nov 22
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
6:14am
6-K
0m9qjmt1w
27 Oct 22
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
7:38am
6-K
uxn5d95ie6ylyfb86
21 Oct 22
Vesting of awards under the Long Term Incentive Plan
6:09am
6-K
b71l5l0
11 Oct 22
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
6:49am